GlassScriptPhysician profile
Archana Verma
NPI 1821046087
$6,341.13
in general payments reported to CMS, 2019-2025
35 companies · $672 in 2025
The $672 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,291 · 2020: $141 · 2021: $563 · 2022: $710 · 2023: $933 · 2024: $2,032 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,731 · Travel and Lodging: $906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,730.59 |
| Travel and Lodging | $906.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,434.76 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Boston Scientific Corporation | $1,361.04 | 2021-2024 | Exalt Model D, Compliance Endokit, Acquire |
| Janssen Biotech, INC. | $757.39 | 2019-2024 | Stelara, Tremfya, Simponi |
| Pfizer INC. | $473.03 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $271.81 | 2019-2025 | Gattex, Entyvio |
| Olympus Corporation of The Americas | $218.62 | 2019 | |
| Celgene Corporation | $199.84 | 2023-2024 | Zeposia |
| Merit Medical Systems INC | $135.00 | 2025 | Esophyx |
| Erbe USA INC | $127.53 | 2024 | Vio3 |
| Janssen Scientific Affairs, LLC | $122.83 | 2019 | |
| Apollo Endosurgery US INC | $118.94 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $115.24 | 2024 | Zeposia |
| Medtronic, INC. | $112.45 | 2021-2022 | |
| Braintree Laboratories, INC. | $97.08 | 2019-2023 | Sutab |
| Phathom Pharmaceuticals, INC. | $97.02 | 2025 | Voquezna |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumendi LLC | $92.55 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.43 | 2021 | |
| Ucb, INC. | $70.90 | 2019-2024 | Cimzia |
| Amgen INC. | $66.98 | 2021-2023 | Amjevita, Avsola |
| Merck Sharp & Dohme LLC | $43.07 | 2019-2021 | |
| Genzyme Corporation | $41.80 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $39.38 | 2021-2024 | |
| Ardelyx, INC. | $35.07 | 2023 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $34.26 | 2021 | |
| Endogastric Solutions, INC | $31.77 | 2019 | |
| Covidien LP | $21.97 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.31 | 2023 | Cyltezo |
| Qol Medical, LLC | $19.23 | 2020 | |
| Shire North American Group INC | $15.73 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.10 | 2023 | Rebyota |
| Abbott Laboratories | $13.50 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $13.49 | 2023 | Dupixent |
| Fresenius Kabi USA, LLC | $13.42 | 2024 | Idacio |
| Micro-Tech Endoscopy USA, INC. | $11.69 | 2023 | Rapide Balloon |
| Allergan, INC. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Archana Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.